Skip to main content
An official website of the United States government
Email

Connecting Awardees with Regulatory Experts (CARE) Program

Apply to 2024 CARE Program

Application Deadline: Friday, March 8, 2024

 

The Connecting Awardees with Regulatory Experts (CARE) program is an interagency collaboration between the National Cancer Institute (NCI) and the Food and Drug Administration (FDA).  The goal of the program is to connect small businesses with the FDA and support communications with regulators early in the technology development process. 

To learn more about the history of the CARE program, please read our mini review in Clinical and Translational Science. 

Eligibility

The CARE program is open to SBIR/STTR awardees who have not participated in the CARE program previously or discussed their technology with any FDA centers, including the Center for Biologics Evaluation and Research (CBER), the Center for Drug Evaluation and Research (CDER), and the Center for Devices and Radiological Health (CDRH).

See the list below of participating NIH Institutes and their points of contact:

Organization

Point of Contact

National Cancer Institute (NCI)

Swamy Tripurani
swamy.tripurani@nih.gov

National Heart, Lung, and Blood Institute (NHLBI)

Stephanie Davis

stephanie.davis3@nih.gov

National Institute of Aging (NIA)

Rajesh Kumar

rajesh.kumar3@nih.gov

National Institute of Biomedical Imaging and Bioengineering (NIBIB)

Kari Ashmont

nibib-sbir@mail.nih.gov

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Antonello Pileggi

antonello.pileggi@nih.gov

NHLBI, NIA, NIBIB, and NICHD will only accept CARE applications for technologies regulated by CBER and CDRH. For more information, please get in touch with the point of contact listed above. 

Visit our Regulatory Resources page for curated links to key FDA guidance documents, regulatory education webinars, and point-of-contact information at each FDA center. These resources help small businesses navigate the complex regulatory landscape and better understand the regulatory requirements for various technologies.

Note: The CARE Program does not replace any formal or informal meetings that the FDA encourages or requires. 

  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Connecting Awardees with Regulatory Experts (CARE) Program was originally published by the National Cancer Institute.”

Email